{"transactions":[{"id":1491706,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-04T16:30:21.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":false,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001415889-24-015368","document":"form4-06042024_040616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000141588924015368/form4-06042024_040616.xml","form_type":"4"}},{"id":1491705,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T16:30:21.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":true,"shares":4660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":33523,"source":{"system":"sec-edgar","filing":"0001415889-24-015368","document":"form4-06042024_040616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000141588924015368/form4-06042024_040616.xml","form_type":"4"}},{"id":1594913,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T16:58:53.000Z","date":"2024-03-04","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":1.25,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.269, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":28863,"source":{"system":"sec-edgar","filing":"0001209191-24-004385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919124004385/doc4.xml","form_type":"4"}},{"id":1594912,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-05T16:58:53.000Z","date":"2024-03-01","kind":"purchase","planned":false,"acquired":true,"shares":8500,"price":1.23,"value":10455.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.2393, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":22863,"source":{"system":"sec-edgar","filing":"0001209191-24-004385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919124004385/doc4.xml","form_type":"4"}},{"id":1866521,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T16:50:10.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-23-034399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919123034399/doc4.xml","form_type":"4"}},{"id":1866520,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T16:50:10.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":4660,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001209191-23-034399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919123034399/doc4.xml","form_type":"4"}},{"id":1866519,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T16:50:10.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":8.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-23-034399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919123034399/doc4.xml","form_type":"4"}},{"id":1866518,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T16:50:10.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":4507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":14363,"source":{"system":"sec-edgar","filing":"0001209191-23-034399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919123034399/doc4.xml","form_type":"4"}},{"id":2049497,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-20T17:08:55.000Z","date":"2022-11-08","kind":"gift","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9856,"source":{"system":"sec-edgar","filing":"0001209191-23-004300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919123004300/doc4.xml","form_type":"4"}},{"id":2234179,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T23:44:15.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":18000,"derivative":{"exercise_price":4.18,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-036476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122036476/doc4.xml","form_type":"4"}},{"id":2240753,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-06-07T21:18:52.000Z","date":"2022-06-04","kind":"exercise","acquired":false,"shares":7059,"price":9.5,"value":67060.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted on June 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested on June 4, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested on June 4, 2022."}],"balance_after":0,"derivative":{"exercise_date":"2022-06-04","expiration_date":"2022-06-04","underlying":"Common Stock","underlying_shares":7059},"source":{"system":"sec-edgar","filing":"0001628280-22-016491","document":"wf-form4_165463670638202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828022016491/wf-form4_165463670638202.xml","form_type":"4"}},{"id":2240752,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T21:18:52.000Z","date":"2022-06-04","kind":"grant","acquired":true,"shares":7059,"price":9.5,"value":67060.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."}],"balance_after":27477,"source":{"system":"sec-edgar","filing":"0001628280-22-016491","document":"wf-form4_165463670638202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828022016491/wf-form4_165463670638202.xml","form_type":"4"}},{"id":2241556,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T17:30:51.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-22-034601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919122034601/doc4.xml","form_type":"4"}},{"id":2241555,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T17:30:51.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."}],"balance_after":4507,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-22-034601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919122034601/doc4.xml","form_type":"4"}},{"id":2241554,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T17:30:51.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":14.48,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-22-034601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919122034601/doc4.xml","form_type":"4"}},{"id":2241553,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T17:30:51.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":3356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":13856,"source":{"system":"sec-edgar","filing":"0001209191-22-034601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919122034601/doc4.xml","form_type":"4"}},{"id":2241552,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T17:30:51.000Z","date":"2022-05-16","kind":"gift","acquired":false,"shares":709,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001209191-22-034601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919122034601/doc4.xml","form_type":"4"}},{"id":2248144,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-06-02T16:45:16.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":9474,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock."}],"balance_after":9474,"derivative":{"exercise_date":"2023-05-31","underlying":"Common Stock","underlying_shares":9474},"source":{"system":"sec-edgar","filing":"0001628280-22-016006","document":"wf-form4_165418829909139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828022016006/wf-form4_165418829909139.xml","form_type":"4"}},{"id":2485233,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T16:52:54.000Z","date":"2021-11-23","kind":"gift","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11209,"source":{"system":"sec-edgar","filing":"0001209191-21-067863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919121067863/doc4.xml","form_type":"4"}},{"id":2563085,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-21T21:08:26.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors."}],"balance_after":15000,"derivative":{"exercise_price":28.83,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-057061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919121057061/doc4.xml","form_type":"4"}},{"id":2678159,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-06-09T00:01:35.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":7059,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock."}],"balance_after":7059,"derivative":{"exercise_date":"2022-06-04","underlying":"Common Stock","underlying_shares":7059},"source":{"system":"sec-edgar","filing":"0001593968-21-001570","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000159396821001570/primary_01.xml","form_type":"4"}},{"id":2680700,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-04T20:07:41.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."}],"balance_after":3356,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-21-038455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919121038455/doc4.xml","form_type":"4"}},{"id":2680699,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:07:41.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date."}],"balance_after":12250,"derivative":{"exercise_price":21.9,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-038455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919121038455/doc4.xml","form_type":"4"}},{"id":2684424,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-06-04T00:02:08.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":8303,"price":11.64,"value":96646.92,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted on June 1, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested on June 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested on June 1, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-01","expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":8303},"source":{"system":"sec-edgar","filing":"0001593968-21-001521","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000159396821001521/primary_01.xml","form_type":"4"}},{"id":2684423,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T00:02:08.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":8303,"price":11.64,"value":96646.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."}],"balance_after":20418,"source":{"system":"sec-edgar","filing":"0001593968-21-001521","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000159396821001521/primary_01.xml","form_type":"4"}},{"id":2955219,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-08T00:56:12.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":21009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020."}],"balance_after":21009,"derivative":{"exercise_price":21,"expiration_date":"2030-12-02","underlying":"Common Stock","underlying_shares":21009},"source":{"system":"sec-edgar","filing":"0001209191-20-062050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919120062050/doc4.xml","form_type":"4"}},{"id":3004457,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-10-19T20:17:58.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":2200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted on October 15, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested on October 15, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested on October 15, 2020."}],"balance_after":0,"derivative":{"exercise_date":"2020-10-15","expiration_date":"2020-10-15","underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001593968-20-002069","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000159396820002069/primary_01.xml","form_type":"4"}},{"id":3004456,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-19T20:17:58.000Z","date":"2020-10-15","kind":"grant","acquired":true,"shares":2200,"price":10.36,"value":22792.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."}],"balance_after":12115,"source":{"system":"sec-edgar","filing":"0001593968-20-002069","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000159396820002069/primary_01.xml","form_type":"4"}},{"id":3118316,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-08T17:28:35.000Z","date":"2020-06-06","kind":"exercise","acquired":false,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-20-035031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120035031/doc4.xml","form_type":"4"}},{"id":3118315,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2020-06-08T17:28:35.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date."}],"balance_after":16500,"derivative":{"exercise_price":1.41,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-20-035031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120035031/doc4.xml","form_type":"4"}},{"id":3118314,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T17:28:35.000Z","date":"2020-06-06","kind":"exercise","acquired":true,"shares":7333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":16709,"source":{"system":"sec-edgar","filing":"0001209191-20-035031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120035031/doc4.xml","form_type":"4"}},{"id":3127775,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Buy Restricted Stock Unit (RSU)","published_at":"2020-06-02T22:23:53.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":8303,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock."}],"balance_after":8303,"derivative":{"exercise_date":"2021-06-01","underlying":"Common Stock","underlying_shares":8303},"source":{"system":"sec-edgar","filing":"0001628280-20-008848","document":"wf-form4_159113661548632.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828020008848/wf-form4_159113661548632.xml","form_type":"4"}},{"id":3131158,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-05-29T19:46:53.000Z","date":"2020-05-28","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted on May 28, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested on May 28, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested on May 28, 2020."}],"balance_after":0,"derivative":{"exercise_date":"2020-05-28","expiration_date":"2020-05-28","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-20-008622","document":"wf-form4_159078159558808.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828020008622/wf-form4_159078159558808.xml","form_type":"4"}},{"id":3131157,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T19:46:53.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":6000,"price":10.99,"value":65940.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."}],"balance_after":9915,"source":{"system":"sec-edgar","filing":"0001628280-20-008622","document":"wf-form4_159078159558808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828020008622/wf-form4_159078159558808.xml","form_type":"4"}},{"id":3226888,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T16:27:05.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120016086/doc4.xml","form_type":"4"}},{"id":3226887,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T16:27:05.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":8876,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120016086/doc4.xml","form_type":"4"}},{"id":3226886,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-04T16:27:05.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":8876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":9376,"source":{"system":"sec-edgar","filing":"0001209191-20-016086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120016086/doc4.xml","form_type":"4"}},{"id":3302644,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-24T18:34:11.000Z","date":"2020-01-23","kind":"disposition_to_issuer","acquired":false,"shares":6389,"price":55.6,"value":355228.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting of the shares  in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $355,228.40, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68)."}],"balance_after":0,"derivative":{"exercise_price":12.4,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":6389},"source":{"system":"sec-edgar","filing":"0001209191-20-004926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120004926/doc4.xml","form_type":"4"}},{"id":3302643,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-24T18:34:11.000Z","date":"2020-01-23","kind":"disposition_to_issuer","acquired":false,"shares":27015,"price":54,"value":1458810.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, which provided for vesting of the shares in equal monthly installments over a three year period such that the option would be fully vested on December 19, 2021, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,458,810.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68)."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":27015},"source":{"system":"sec-edgar","filing":"0001209191-20-004926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919120004926/doc4.xml","form_type":"4"}},{"id":3392396,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Buy Restricted Stock Unit (RSU)","published_at":"2019-10-17T19:15:20.000Z","date":"2019-10-15","kind":"grant","acquired":true,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock."}],"balance_after":2200,"derivative":{"exercise_date":"2020-10-15","underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001628280-19-012371","document":"wf-form4_157133968967988.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828019012371/wf-form4_157133968967988.xml","form_type":"4"}},{"id":3495448,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-10T18:54:31.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":6389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over the 12 months following June 7, 2019, provided that the option will be fully vested on the date of the Issuer's next annual stockholder meeting."}],"balance_after":6389,"derivative":{"exercise_price":12.4,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":6389},"source":{"system":"sec-edgar","filing":"0001209191-19-035982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919119035982/doc4.xml","form_type":"4"}},{"id":3495475,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-10T16:51:09.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."}],"balance_after":7333,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-19-035832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919119035832/doc4.xml","form_type":"4"}},{"id":3507942,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Buy Restricted Stock Unit (RSU)","published_at":"2019-05-31T00:37:36.000Z","date":"2019-05-28","kind":"grant","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock."}],"balance_after":6000,"derivative":{"exercise_date":"2020-05-28","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001628280-19-007410","document":"wf-form4_155926304058506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828019007410/wf-form4_155926304058506.xml","form_type":"4"}},{"id":3507941,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-05-31T00:37:36.000Z","date":"2019-05-30","kind":"exercise","acquired":false,"shares":2915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units were granted on January 30, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested on May 30, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested on May 30, 2019."}],"balance_after":0,"derivative":{"exercise_date":"2019-05-30","expiration_date":"2019-05-30","underlying":"Common Stock","underlying_shares":2915},"source":{"system":"sec-edgar","filing":"0001628280-19-007410","document":"wf-form4_155926304058506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828019007410/wf-form4_155926304058506.xml","form_type":"4"}},{"id":3507940,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T00:37:36.000Z","date":"2019-05-30","kind":"exercise","acquired":true,"shares":2915,"price":9.91,"value":28887.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."}],"balance_after":3915,"source":{"system":"sec-edgar","filing":"0001628280-19-007410","document":"wf-form4_155926304058506.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000162828019007410/wf-form4_155926304058506.xml","form_type":"4"}},{"id":3681654,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true}}],"security":"Right to Buy Restricted Stock Unit (RSU)","published_at":"2019-02-01T01:58:48.000Z","date":"2019-01-30","kind":"exercise","acquired":true,"shares":2915,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted Stock Units will vest 4 months from the grant date and will be automatically settled in shares of common stock."}],"balance_after":2915,"derivative":{"exercise_date":"2019-05-30","underlying":"Common Stock","underlying_shares":2915},"source":{"system":"sec-edgar","filing":"0001437749-19-001629","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000143774919001629/rdgdoc.xml","form_type":"4"}},{"id":3696733,"issuer":{"id":6447,"kind":"organization","name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-01-14T19:25:46.000Z","date":"2019-01-11","kind":"purchase","acquired":true,"shares":525,"price":11.62,"value":6100.5,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001437749-19-000820","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1005286/000143774919000820/rdgdoc.xml","form_type":"4"}},{"id":3720807,"issuer":{"id":152202,"kind":"organization","name":"Synthorx, Inc.","symbol":"THOR"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T16:07:16.000Z","date":"2018-12-19","kind":"grant","acquired":true,"shares":27015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in equal monthly installments over a three year period such that the option is fully vested on December 19, 2021, subject to full vesting acceleration upon a change in control (as defined in Synthorx's equity incentive plan)."}],"balance_after":27015,"derivative":{"exercise_price":14,"expiration_date":"2028-12-18","underlying":"Common Stock","underlying_shares":27015},"source":{"system":"sec-edgar","filing":"0001209191-18-063891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919118063891/doc4.xml","form_type":"4"}},{"id":3899676,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T16:02:44.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":18.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-036652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919118036652/doc4.xml","form_type":"4"}},{"id":3927618,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-17T19:34:36.000Z","date":"2018-05-16","kind":"purchase","acquired":true,"shares":500,"price":19.12,"value":9560.0,"ownership":{"direct":true},"balance_after":500,"source":{"system":"sec-edgar","filing":"0001209191-18-031200","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919118031200/doc4.xml","form_type":"4"}},{"id":4278718,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-16T19:45:12.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":24.58,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-040672","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919117040672/doc4.xml","form_type":"4"}},{"id":4480391,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-26T17:37:36.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable in 36 equal monthly installments through January 25, 2020, subject to the reporting person's continuous service as of such vesting dates."}],"balance_after":16000,"derivative":{"exercise_price":27.3,"expiration_date":"2027-01-24","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-17-005760","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1304113/000120919117005760/doc4.xml","form_type":"4"}},{"id":4592169,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel & Crp Sec"}}],"security":"Performance-Based Restricted Stock Units","published_at":"2016-09-30T17:54:18.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":14474,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares subject to the performance-based restricted stock unit (the \"PSUs\") is based on deemed satisfaction of all applicable performance goals at the maximum levels."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares subject to the performance-based restricted stock unit (the \"PSUs\") is based on deemed satisfaction of all applicable performance goals at the maximum levels."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2020-02-18","underlying":"Common Stock","underlying_shares":14474},"source":{"system":"sec-edgar","filing":"0001209191-16-143389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143389/doc4.xml","form_type":"4"}},{"id":4592168,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel & Crp Sec"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:54:18.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":38530,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":35.77,"expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":38530},"source":{"system":"sec-edgar","filing":"0001209191-16-143389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143389/doc4.xml","form_type":"4"}},{"id":4592167,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel & Crp Sec"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-30T17:54:18.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":40860,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":64.165,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":40860},"source":{"system":"sec-edgar","filing":"0001209191-16-143389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143389/doc4.xml","form_type":"4"}},{"id":4592166,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel & Crp Sec"}}],"security":"Common Stock","published_at":"2016-09-30T17:54:18.000Z","date":"2016-09-28","kind":"disposition_to_issuer","acquired":false,"shares":22920,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents unvested restricted stock units (the \"RSUs\") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes.  In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-143389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143389/doc4.xml","form_type":"4"}},{"id":4592165,"issuer":{"id":181987,"kind":"organization","name":"MEDIVATION, INC.","symbol":"MDVN"},"owners":[{"id":90276,"kind":"person","name":"Powell Andrew Kenneth William","position":1,"cik":"0001304113","reported_name":"Powell Andrew Kenneth William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel & Crp Sec"}}],"security":"Common Stock","published_at":"2016-09-30T17:54:18.000Z","date":"2016-09-28","kind":"other","acquired":false,"shares":5597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Purchaser\"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-143389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1011835/000120919116143389/doc4.xml","form_type":"4"}}]}